Endocrinology

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

A review of 9 novel drugs approved by the US Food and Drug Administration during the second quarter of 2026.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

A review of 22 novel drugs approved by the US Food and Drug Administration during the first half of 2026, with links to coverage from MJH Life Sciences publications.

Catch up on major trial results, groundbreaking FDA decisions, and key clinician insights from major endocrinology conferences.

The FDA has approved veligrotug-vvze for thyroid eye disease regardless of activity or duration.

Lindsay Fourman, MD, discusses early real-world data exploring the use of GLP-1 receptor agonists alongside metreleptin in lipodystrophy.

Igudesman discusses her presentation at ENDO 2026, during which she covered the importance of managing obesity with lifestyle changes in patients with T1D.

Rishi Wadhera, MD, MPP, MPhil, addresses performance metrics, cross-specialty prescribing, and the policy forces reshaping the cardiometabolic care cascade.

Rishi Wadhera, MD, MPP, MPhil, discusses where the cardiometabolic care cascade is failing most consequentially at the 10th Annual Heart in Diabetes Meeting.

First placebo-controlled phase 3 METRE-PL data show prevalent metabolic burden in familial partial lipodystrophy (FPLD) despite standard therapy.

Corxel reported CX11 met phase 2 endpoints in adults with obesity or overweight, with up to 11.5% weight loss at 36 weeks.

In the final segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

In the fourth segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

In the third segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

In the second segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

In the first segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

Michal Meron, MD, discusses her recent study indicating the potential role of the TYG index in predicting liver disease among patients without diabetes with confirmed MASLD.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

MOMENTUM data suggest hypercortisolism prevalence reached 43.6% among individuals with resistant hypertension and an eGFR below 45 mL/min/1.73 m².

A secret shopper study of 49 websites selling GLP-1 receptor agonists found more than 90% issued a prescription, often without bloodwork, photo verification, or clinician interaction.

Diana Varghese, MD, discusses her recent study noting a 9% prevalence of PA among patients with incident hypertension and providing targets for further screening strategies.

Data from the ongoing open-label extensions of PATHFNDR-1 and PATHFNDR-2, presented at ENDO 2026, highlight the drug’s efficacy in reducing IGF-1.

Crinecerfont enabled sustained GC dose reductions over 2 years, with nearly 70% of adults with classic CAH reaching physiologic dosing.

Gafni discusses the primary results of the phase 3 CALIBRATE trial, testing the investigational oral calcilytic in this difficult-to-treat disease state.